{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:17:09Z","timestamp":1787318229776,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012453","name":"Providence Health Care","doi-asserted-by":"publisher","award":["PHC\/VCH Knowledge Translation Challenge"],"award-info":[{"award-number":["PHC\/VCH Knowledge Translation Challenge"]}],"id":[{"id":"10.13039\/100012453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For people with opioid use disorder who are not responding to oral opioid agonist treatment, evidence supports the effectiveness of injectable opioid agonist treatment with injectable hydromorphone (an opioid analgesic) and diacetylmorphine (pharmaceutical grade heroin). While this treatment is effective at reducing illicit opioid use, concurrent cocaine use is prevalent. Dextroamphetamine (a central nervous system stimulant) has been found to be a safe and effective treatment for cocaine dependence among people receiving injectable opioid agonist treatment in Europe. We present the first report of dextroamphetamine prescribing offered for the treatment of stimulant use disorder among a patient receiving iOAT outside of a clinical trial. This case report can be used to inform clinical practice in the treatment of cocaine use disorder, an area where interventions are currently lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Dextroamphetamine was prescribed to a 51-year-old male who was diagnosed with concurrent opioid and stimulant use disorder in an injectable opioid agonist treatment clinic in Vancouver, Canada. He reported smoking crack cocaine daily for more than two decades and was experiencing health consequences associated with this use. He presented to his routine physician visit with the goal of reducing his cocaine use and was prescribed dextroamphetamine for the treatment of stimulant use disorder. After 4-weeks the patient was tolerating the medication with no observed adverse events and was achieving his therapeutic goal of reducing his cocaine use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dextroamphetamine can be prescribed to support patients with stimulant use disorder to reduce or stop their use of cocaine. The case demonstrated that when dextroamphetamine was prescribed, a significant reduction in cocaine use was experienced among a patient that had been regularly using cocaine on a daily basis for many years. Daily contact with care for the opioid medication promoted adherence to the stimulant medication and allowed for monitoring of dose and tolerance. Settings where patients are in regular contact with care such as oral and injectable opioid agonist treatment clinics serve as a suitable location to integrate dextroamphetamine prescribing for patients that use illicit stimulants to reduce use and associated harms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-021-00500-9","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T09:03:07Z","timestamp":1621501387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8570-5717","authenticated-orcid":false,"given":"Heather","family":"Palis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Oviedo-Joekes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"500_CR1","unstructured":"Centers for Disease Control and Prevention. Drug and opioid-involved overdose deaths\u2014United States, 2013\u20132017. 2019."},{"key":"500_CR2","unstructured":"Statistics Canada. Changes in life expectancy by selected causes of death. 2017."},{"key":"500_CR3","unstructured":"British Columbia Coroner's Service. Fentanyl-detected illicit drug toxicity deaths. 2019."},{"issue":"5","key":"500_CR4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/add.14878","volume":"115","author":"B Hoots","year":"2020","unstructured":"Hoots B, Vivolo-Kantor A, Seth P. The rise in non-fatal and fatal overdoses involving stimulants with and without opioids in the United States. Addiction. 2020;115(5):946\u201358.","journal-title":"Addiction"},{"key":"500_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","volume":"193","author":"MS Ellis","year":"2018","unstructured":"Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14\u201320.","journal-title":"Drug Alcohol Depend"},{"key":"500_CR6","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane Library 2014.","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"500_CR7","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009(3):CD002209.","DOI":"10.1002\/14651858.CD002209.pub2"},{"issue":"4","key":"500_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1360-0443.2003.00335.x","volume":"98","author":"RP Mattick","year":"2003","unstructured":"Mattick RP, Ali R, White JM, O\u2019Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003;98(4):441\u201352.","journal-title":"Addiction"},{"key":"500_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jsat.2019.03.012","volume":"101","author":"EP Oviedo-Joekes","year":"2019","unstructured":"Oviedo-Joekes EP, Guh H, Marchand D, Brissette SH, MacDonald S, Lock S, Anis K, Marsh DC, Schechter M. Treatment with injectable hydromorphone: comparing retention in double blind and open label treatment periods. J Subst Abuse Treat. 2019;101:50\u20134.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"500_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamapsychiatry.2016.0109","volume":"73","author":"E Oviedo-Joekes","year":"2016","unstructured":"Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, Harrison S, Janmohamed A, Anis AH, Krausz M, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA Psychiat. 2016;73(5):1\u20139.","journal-title":"JAMA Psychiat"},{"issue":"9729","key":"500_CR11","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(10)60349-2","volume":"375","author":"J Strang","year":"2010","unstructured":"Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S, Williams H, Zador D, Evers R, Groshkova T. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet. 2010;375(9729):1885\u201395.","journal-title":"Lancet"},{"issue":"7410","key":"500_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/bmj.327.7410.310","volume":"327","author":"W van den Brink","year":"2003","unstructured":"van den Brink W, Hendriks VM, Blanken P, Koeter MW, van Zwieten BJ, van Ree JM. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ. 2003;327(7410):310.","journal-title":"BMJ"},{"issue":"8","key":"500_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa0810635","volume":"361","author":"E Oviedo-Joekes","year":"2009","unstructured":"Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777\u201386.","journal-title":"N Engl J Med"},{"issue":"1","key":"500_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1192\/bjp.bp.114.149195","volume":"207","author":"J Strang","year":"2015","unstructured":"Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schechter MT, Lintzeris N, Bell J, Pirona A, Oviedo-Joekes E, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addictiondagger. Br J Psychiatry. 2015;207(1):5\u201314.","journal-title":"Br J Psychiatry"},{"issue":"Suppl 2","key":"500_CR15","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/S0924-977X(10)70001-8","volume":"20","author":"P Blanken","year":"2010","unstructured":"Blanken P, van den Brink W, Hendriks VM, Huijsman IA, Klous MG, Rook EJ, Wakelin JS, Barendrecht C, Beijnen JH, van Ree JM. Heroin-assisted treatment in the Netherlands: History, findings, and international context. Eur Neuropsychopharmacol. 2010;20(Suppl 2):S105-158.","journal-title":"Eur Neuropsychopharmacol"},{"key":"500_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12954-016-0100-7","volume":"13","author":"P Roux","year":"2016","unstructured":"Roux P, Lions C, Vilotitch A, Michel L, Mora M, Maradan G, Marcellin F, Spire B, Morel A, Carrieri PM. Correlates of cocaine use during methadone treatment: implications for screening and clinical management (ANRS Methaville study). Harm Reduct J. 2016;13:12.","journal-title":"Harm Reduct J"},{"issue":"1\u20133","key":"500_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.forsciint.2011.01.046","volume":"215","author":"EJ Cone","year":"2012","unstructured":"Cone EJ. Oral fluid results compared to self reports of recent cocaine and heroin use by methadone maintenance patients. Forensic Sci Int. 2012;215(1\u20133):88\u201391.","journal-title":"Forensic Sci Int"},{"key":"500_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2017.05.044","volume":"48","author":"AM Franklyn","year":"2017","unstructured":"Franklyn AM, Eibl JK, Gauthier GJ, Pellegrini D, Lightfoot NE, Marsh DC. The impact of cocaine use in patients enrolled in opioid agonist therapy in Ontario, Canada. Int J Drug Policy. 2017;48:1\u20138.","journal-title":"Int J Drug Policy"},{"key":"500_CR19","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/S0140-6736(09)61420-3","volume":"374","author":"J Marsden","year":"2009","unstructured":"Marsden J, Eastwood B, Bradbury C, Dale-Perera A, Farrell M, Hammond P, Knight J, Randhawa K, Wright C. Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study. Lancet. 2009;374:1262\u201370.","journal-title":"Lancet"},{"key":"500_CR20","doi-asserted-by":"crossref","unstructured":"Castells X, Cunill R, Perez-Mana C, Vidal X, Capella D. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev 2016, 9:CD007380.","DOI":"10.1002\/14651858.CD007380.pub4"},{"key":"500_CR21","doi-asserted-by":"crossref","unstructured":"Perez-Mana C, Castells X, Torrens M, Capella D, Farre M. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database Syst Rev 2013(9):CD009695.","DOI":"10.1002\/14651858.CD009695.pub2"},{"key":"500_CR22","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s00213-020-05563-3","volume":"237","author":"VS Tardelli","year":"2020","unstructured":"Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin FR, Fidalgo TM. Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. Psychopharmacology. 2020;237:2233\u201355.","journal-title":"Psychopharmacology"},{"issue":"8","key":"500_CR23","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1046\/j.1360-0443.2003.00447.x","volume":"98","author":"J Shearer","year":"2003","unstructured":"Shearer J, Wodak A, van Beek I, Mattick RP, Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction. 2003;98(8):1137\u201341.","journal-title":"Addiction"},{"issue":"5","key":"500_CR24","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/sj.npp.1300392","volume":"29","author":"J Grabowski","year":"2004","unstructured":"Grabowski J, Rhoades H, Stotts A, Cowan K, Kopecky C, Dougherty A, Moeller FG, Hassan S, Schmitz J. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology. 2004;29(5):969\u201381.","journal-title":"Neuropsychopharmacology"},{"key":"500_CR25","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/S0140-6736(16)00205-1","volume":"384","author":"M Nuijten","year":"2016","unstructured":"Nuijten M, Blanken P, van de Wetering B, Nuijen B, van den Brink W, Hendriks VM. Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial. Lancet. 2016;384:2226\u201334.","journal-title":"Lancet"},{"key":"500_CR26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/add.14874","volume":"115","author":"P Blanken","year":"2019","unstructured":"Blanken P, Nuijten M, van den Brink W, Hendriks VM. Clinical effects beyond cocaine use of sustained-release dexamphetamine for the treatment of cocaine dependent patients with comorbid opioid dependence: secondary analysis of a double-blind, placebo-controlled randomized trial. Addiction. 2019;115:917\u201323.","journal-title":"Addiction"},{"key":"500_CR27","unstructured":"United Nations Office on Drugs and Crime. World drug report: stimulants. 2019."},{"key":"500_CR28","unstructured":"British Columbia Ministry of Health, British Columbia Centre on Substance Use. Risk mitigation in the context of dual public health emergencies. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2020\/04\/Risk-Mitigation-in-the-Context-of-Dual-Public-Health-Emergencies-v1.5.pdf; 2020."},{"key":"500_CR29","unstructured":"Vancouver Coastal Health. Prescriber guidelines for risk mitigation in the context of dual public health emergencies. 2020."},{"key":"500_CR30","unstructured":"BC Coroners Service. Illicit drug toxicity deaths in BC January 1, 2010\u2013February 28, 2021. 2021."},{"key":"500_CR31","doi-asserted-by":"publisher","first-page":"108176","DOI":"10.1016\/j.drugalcdep.2020.108176","volume":"214","author":"S Slavova","year":"2020","unstructured":"Slavova S, Rock P, Bush HM, Quesinberry D, Walsh SL. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 2020;214:108176.","journal-title":"Drug Alcohol Depend"},{"key":"500_CR32","doi-asserted-by":"publisher","first-page":"102958","DOI":"10.1016\/j.drugpo.2020.102958","volume":"83","author":"J Grebely","year":"2020","unstructured":"Grebely J, Cerd\u00e1 M, Rhodes T. COVID-19 and the health of people who use drugs: what is and what could be? Int J Drug Policy. 2020;83:102958.","journal-title":"Int J Drug Policy"},{"key":"500_CR33","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1360-0443.2009.02717.x","volume":"105","author":"M Longo","year":"2010","unstructured":"Longo M, Wickes W, Smout M, Harrison S, Cahill S, White JM. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction. 2010;105:146\u201354.","journal-title":"Addiction"},{"issue":"2","key":"500_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/clpt.2010.307","volume":"89","author":"GP Galloway","year":"2011","unstructured":"Galloway GP, Buscemi R, Coyle JR, Flower K, Siegrist JD, Fiske LA, Baggott MJ, Li L, Polcin D, Chen CY, et al. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther. 2011;89(2):276\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"500_CR35","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/00004714-200110000-00010","volume":"21","author":"J Grabowski","year":"2001","unstructured":"Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA, Creson D, Moeller FG. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol. 2001;21(5):522\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"500_CR36","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1046\/j.1360-0443.2003.00447.x","volume":"98","author":"J Shearer","year":"2003","unstructured":"Shearer J, Wodak A, van Beek I, Mattick RP, Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction. 2003;98:1137\u201341.","journal-title":"Addiction"},{"issue":"4","key":"500_CR37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40263-020-00711-x","volume":"34","author":"KJ Siefried","year":"2020","unstructured":"Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Pharmacological treatment of methamphetamine\/amphetamine dependence: a systematic review. CNS Drugs. 2020;34(4):337\u201365.","journal-title":"CNS Drugs"},{"issue":"1","key":"500_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13011-020-0253-y","volume":"15","author":"K Marchand","year":"2020","unstructured":"Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment. Subst Abuse Treat Prev Policy. 2020;15(1):7.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"500_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1176\/appi.ps.71101","volume":"71","author":"K Marchand","year":"2020","unstructured":"Marchand K. Bridging gaps to patient-centered care practice. Psychiatr Serv. 2020;71(1):1.","journal-title":"Psychiatr Serv"},{"issue":"3","key":"500_CR40","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/add.12392","volume":"109","author":"J Rance","year":"2014","unstructured":"Rance J, Treloar C. \u201cNot just methadone Tracy\u201d: transformations in service-user identity following the introduction of hepatitis C treatment into Australian opiate substitution settings. Addiction. 2014;109(3):452\u20139.","journal-title":"Addiction"},{"issue":"3","key":"500_CR41","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/ACM.0000000000001294","volume":"92","author":"P Bourgois","year":"2016","unstructured":"Bourgois P, Holmes SM, Sue K, Quesada J. Structural vulnerability: operationalizing the concept to address health disparities in clinical care. Acad Med. 2016;92(3):299\u2013307.","journal-title":"Acad Med"},{"issue":"12","key":"500_CR42","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1111\/add.14755","volume":"114","author":"B Chan","year":"2019","unstructured":"Chan B, Freeman M, Kondo K, Ayers C, Montgomery J, Paynter R, Kansagara D. Pharmacotherapy for methamphetamine\/amphetamine use disorder-a systematic review and meta-analysis. Addiction. 2019;114(12):2122\u201336.","journal-title":"Addiction"},{"issue":"6","key":"500_CR43","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/jamapsychiatry.2015.41","volume":"72","author":"FR Levin","year":"2015","unstructured":"Levin FR, Mariani JJ, Specker S, Mooney M, Mahony A, Brooks DJ, Babb D, Bai Y, Eberly LE, Nunes EV, et al. Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit\/hyperactivity disorder and cocaine use disorder: a randomized clinical trial. JAMA Psychiat. 2015;72(6):593\u2013602.","journal-title":"JAMA Psychiat"},{"key":"500_CR44","unstructured":"Public Defender Association. Addressing methamphetamine: final memorandum and report. Seattle, WA. 2020."},{"key":"500_CR45","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jsat.2019.10.005","volume":"109","author":"JI Tsui","year":"2020","unstructured":"Tsui JI, Mayfield J, Speaker EC, Yakup S, Ries R, Funai H, Leroux BG, Merrill JO. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. J Subst Abuse Treat. 2020;109:80\u20135.","journal-title":"J Subst Abuse Treat"},{"key":"500_CR46","unstructured":"Goodnough A. This addiction treatment works. Why is it so underused? In: New York Times. 2020."},{"issue":"11","key":"500_CR47","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1111\/j.1360-0443.2004.00884.x","volume":"99","author":"RD Weiss","year":"2004","unstructured":"Weiss RD. Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction. 2004;99(11):1382\u201392.","journal-title":"Addiction"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00500-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-021-00500-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00500-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T09:04:41Z","timestamp":1621501481000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-021-00500-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["500"],"URL":"https:\/\/doi.org\/10.1186\/s12954-021-00500-9","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]},"assertion":[{"value":"3 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the participant, who approved the final version of the case profile and confirmed that it accurately reflected his experience. As per communication with the University of British Columbia Research Ethics Board, ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable (No personal identifier is included).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}